Search - tctmd.com

Displaying 141 - 152 of 152

Sort: Relevancy | Date

News Daily News

Drug-eluting Balloons Show Positive Results in Treating In-stent Restenosis

Jason Kahn

October 05, 2012

News Daily News

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

March 15, 2012

News Daily News

Celecoxib Enhances DES Efficacy, But at Clinical Cost

March 15, 2012

News Daily News

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Yael L. Maxwell

March 06, 2012

News Daily News

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Yael L. Maxwell

March 06, 2012

Presentation

Resultados Clínicos y Tratamiento tras Fracaso de SLF: Ausencia de Factores de Riesgo Tradicionales en la Reestenosis Intra Stent (ISR)

Presenter: G. Maluenda

February 15, 2012

News Daily News

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Yael L. Maxwell

February 15, 2012

Presentation

Clinical Outcomes and Treatment After DES Failure: The Absence of Traditional Risk Factors for In-Stent Restenosis (ISR)

Presenter: G. Maluenda

February 15, 2012

Presentation TCT 2012

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

News Conference News

EuroPCR 2011: Novel Technologies with Transformative Potential Stand Out

May 23, 2011

News Conference News

Paclitaxel Balloon Maintains Advantage at 5 Years

Caitlin E. Cox

May 20, 2011

News Daily News

Paclitaxel-Eluting Balloon Effective for DES Restenosis

February 22, 2011

Advertisement

Drug-eluting Balloons Show Positive Results in Treating In-stent Restenosis

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

Celecoxib Enhances DES Efficacy, But at Clinical Cost

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Resultados Clínicos y Tratamiento tras Fracaso de SLF: Ausencia de Factores de Riesgo Tradicionales en la Reestenosis Intra Stent (ISR)

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Clinical Outcomes and Treatment After DES Failure: The Absence of Traditional Risk Factors for In-Stent Restenosis (ISR)

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

EuroPCR 2011: Novel Technologies with Transformative Potential Stand Out

Paclitaxel Balloon Maintains Advantage at 5 Years

Paclitaxel-Eluting Balloon Effective for DES Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content